Sangamo Therapeutics Inc. (SGMO)

24.95
NASDAQ : Health Technology
Prev Close 25.40
Day Low/High 24.66 / 26.85
52 Wk Low/High 3.75 / 27.50
Avg Volume 1.50M
Exchange NASDAQ
Shares Outstanding 84.52M
Market Cap 1.88B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Kite, A Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer

Kite, A Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer

-- Kite to Receive Exclusive License to Leverage Sangamo's Gene Editing Technology in Allogeneic and Autologous Cell Therapy Programs in Oncology --

Biotech Gold Rush Starts to Pick Up; Xerox, Fujifilm Saga Continues -- ICYMI

Biotech Gold Rush Starts to Pick Up; Xerox, Fujifilm Saga Continues -- ICYMI

Here's what you need to know now for Wednesday, Feb. 14.

Biotech Heats Up as Fear of Missing Out Returns

Biotech Heats Up as Fear of Missing Out Returns

It's hard to believe the bounce will continue to run in V-shaped fashion.

Seeing Good Action in Several Stocks, Buying More MJ, Gold

Seeing Good Action in Several Stocks, Buying More MJ, Gold

It is a very different market environment now which can be very rewarding depending on your style.

Focused on Two Sectors

Focused on Two Sectors

If we have a little consolidating action here the buyers will start pushing again.

Indexes Are Holding Up Well, For Now

Indexes Are Holding Up Well, For Now

There are signs of stabilization, but the market is still digesting some very big swings.

Traders Need to Adapt to a New Reality

Traders Need to Adapt to a New Reality

The volatility trade that propped up markets is no longer available.

This Market Badly Needs a Rest

This Market Badly Needs a Rest

It would be a longer-term positive if the overbought conditions are alleviated.

In This Booming Stock Market, Think Like a Programmer Not a Critic

In This Booming Stock Market, Think Like a Programmer Not a Critic

What drives the trading action are structural issues, not macroeconomic news events or political drama.

How Trading Notes Can Increase Your Profits

How Trading Notes Can Increase Your Profits

Inertia is your biggest enemy in this market.

Selling Action Is Upon Us

Selling Action Is Upon Us

There is still a very strong appetite for individual stocks with momentum.

This Is a Great Market for Stock Traders

This Is a Great Market for Stock Traders

If you're looking for something negative to say about this action about the only thing you might argue is that the action is too positive.

First Week Of SGMO August 2018 Options Trading

First Week Of SGMO August 2018 Options Trading

Investors in Sangamo Therapeutics Inc saw new options become available this week, for the August 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Focused on Stock Picking Through This Volatility

Focused on Stock Picking Through This Volatility

I'm trying not to be sucked into the market-timing game and am looking mainly at setups in individual stocks.

The Return of Stock Market Volatility Can Create Stellar Opportunities

The Return of Stock Market Volatility Can Create Stellar Opportunities

But you need to be selective and have discipline.

SGMO Crosses Above Average Analyst Target

In recent trading, shares of Sangamo Therapeutics Inc have crossed above the average analyst 12-month target price of $15.50, changing hands for $16.20/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Gains Elude Market as Momentum Withers

Gains Elude Market as Momentum Withers

Financial sector among the few bright spots.

TheStreet Quant Rating: D (Sell)